AR119338A1 - IMMUNOCONJUGATES COMPRISING A MUTANT INTERLEUKIN-2 (IL-2) POLYPEPTIDE AND AN ANTIBODY THAT BINDS CD8 - Google Patents

IMMUNOCONJUGATES COMPRISING A MUTANT INTERLEUKIN-2 (IL-2) POLYPEPTIDE AND AN ANTIBODY THAT BINDS CD8

Info

Publication number
AR119338A1
AR119338A1 ARP200101876A ARP200101876A AR119338A1 AR 119338 A1 AR119338 A1 AR 119338A1 AR P200101876 A ARP200101876 A AR P200101876A AR P200101876 A ARP200101876 A AR P200101876A AR 119338 A1 AR119338 A1 AR 119338A1
Authority
AR
Argentina
Prior art keywords
immunoconjugates
polypeptide
binds
antibody
mutant
Prior art date
Application number
ARP200101876A
Other languages
Spanish (es)
Inventor
Christian Klein
Pablo Umaa
Inja Waldhauer
Anne Freimoser-Grundschober
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR119338A1 publication Critical patent/AR119338A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere de manera general a inmunoconjugados, en particular inmunoconjugados que comprenden un polipéptido interleuquina-2 mutante y un anticuerpo que se une a CD8. Además, la presente se refiere a moléculas polinucleótidas codificantes de los inmunoconjugados, y vectores y células huésped que comprenden dichas moléculas polinucleótidas. La misma se refiere además a métodos para producir los inmunoconjugados mutantes, composiciones farmacéuticas que los comprenden, y usos de los mismos.This relates generally to immunoconjugates, in particular immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to CD8. Furthermore, the present invention relates to polynucleotide molecules encoding immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. It further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising them, and uses thereof.

ARP200101876A 2019-07-02 2020-07-02 IMMUNOCONJUGATES COMPRISING A MUTANT INTERLEUKIN-2 (IL-2) POLYPEPTIDE AND AN ANTIBODY THAT BINDS CD8 AR119338A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19183829 2019-07-02

Publications (1)

Publication Number Publication Date
AR119338A1 true AR119338A1 (en) 2021-12-09

Family

ID=67296960

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101876A AR119338A1 (en) 2019-07-02 2020-07-02 IMMUNOCONJUGATES COMPRISING A MUTANT INTERLEUKIN-2 (IL-2) POLYPEPTIDE AND AN ANTIBODY THAT BINDS CD8

Country Status (6)

Country Link
EP (1) EP3994169A1 (en)
JP (1) JP2022538139A (en)
CN (1) CN114051500A (en)
AR (1) AR119338A1 (en)
TW (1) TW202115115A (en)
WO (1) WO2021001289A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102353497B1 (en) 2013-10-18 2022-01-21 유니베르시다데 도 미노 Peptide composition and respective uses
CA3069105A1 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
MX2023004598A (en) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusions with cd8 antigen binding molecules for modulating immune cell function.
GB2623654A (en) 2021-05-19 2024-04-24 Asher Biotherapeutics Inc Il-21 polypeptides and targeted constructs
EP4373854A1 (en) * 2021-07-20 2024-05-29 Inhibrx, Inc. Cd8-binding polypeptides and uses thereof
WO2023004305A1 (en) * 2021-07-20 2023-01-26 Inhibrx, Inc. Cd8-targeted modified il-2 polypeptides and uses thereof
WO2024086827A2 (en) * 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
CN116041539B (en) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 IL-2 mutant immunoconjugates

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186567A (en) 1977-04-18 1980-02-05 Hitachi Metals, Ltd. Ornament utilizing rare earth-cobalt magnet
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
JP2524586B2 (en) 1985-06-26 1996-08-14 シタス コーポレイション Solubilization of proteins for pharmaceutical compositions utilizing polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334351D1 (en) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetic binding protein for tumor markers
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (en) 1999-10-04 2006-03-16 Medicago Inc. METHOD FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NIGTROGEN.
JP2003516755A (en) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド Shotgun scanning, a combined method for mapping functional protein epitopes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP2005507870A (en) 2001-08-13 2005-03-24 ユニバーシティ・オブ・サザン・カリフォルニア Low toxicity interleukin-2 mutant
ES2381025T3 (en) 2001-12-04 2012-05-22 Merck Patent Gmbh Immunocytokines with modulated selectivity
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
BRPI0508761A (en) 2004-03-31 2007-08-14 Genentech Inc humanized antibody, composition comprising a humanized antibody, isolated nucleic acid, vector, host cell, humanized antibody production process, tgf-beta dysfunction treatment method, tgf-beta detection method, manufactured article and method of treating cancer
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ES2403055T3 (en) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anti-P-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
WO2006082515A2 (en) 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
PL1999154T3 (en) 2006-03-24 2013-03-29 Merck Patent Gmbh Engineered heterodimeric protein domains
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CA2663832C (en) 2006-09-20 2013-02-05 Dge Dr.-Ing. Guenther Engineering Gmbh Method and device for separating methane and carbon dioxide from biogas
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2467165B1 (en) 2009-08-17 2015-01-07 Roche Glycart AG Targeted immunoconjugates
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
RS59589B1 (en) 2010-11-05 2019-12-31 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
DK2673294T3 (en) 2011-02-10 2016-05-30 Roche Glycart Ag MUTANT INTERLEUKIN-2 POLYPEPTIDES
MY163539A (en) 2011-03-29 2017-09-15 Roche Glycart Ag Antibody fc variants
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
PT2794905T (en) 2011-12-20 2020-06-30 Medimmune Llc Modified polypeptides for bispecific antibody scaffolds
CN104125852B9 (en) 2012-02-15 2017-05-17 弗·哈夫曼-拉罗切有限公司 Fc-receptor based affinity chromatography
NZ630568A (en) 2012-04-20 2017-06-30 Merus Nv Methods and means for the production of ch3 domain-comprising molecules
CA3069105A1 (en) * 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
KR102713874B1 (en) 2017-08-11 2024-10-10 제넨테크, 인크. Anti-CD8 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3994169A1 (en) 2022-05-11
CN114051500A (en) 2022-02-15
JP2022538139A (en) 2022-08-31
TW202115115A (en) 2021-04-16
WO2021001289A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
AR119338A1 (en) IMMUNOCONJUGATES COMPRISING A MUTANT INTERLEUKIN-2 (IL-2) POLYPEPTIDE AND AN ANTIBODY THAT BINDS CD8
CR20190426A (en) IMMUNOCONJUGATES
CY1117842T1 (en) IL-2 MUTUAL POLYPeptides
CO2019003154A2 (en) Anti-PD-1 antibodies and their uses
CO2018010538A2 (en) Specific poliovirus receptor (rvp) antibodies
CO2021002907A2 (en) Antibody Constructs for cldn18.2 and cd3
DOP2019000165A (en) ANTI-OX40 ANTIBODIES AND ITS USES
DOP2018000258A (en) ANTI-CD40 ANTIBODIES AND THEIR USES
BR112017007093A2 (en) compositions and methods of use for enhancing immune response and cancer therapy
BR112018001683A2 (en) recombinant adenovirus, composition, use of an adenovirus or composition, and non-human simian adenovirus.
UY37456A (en) IMMUNOGLOBULINAS AND ITS USES
BR112021019334A2 (en) Heavy chain antibodies that bind to psma
CO2018012497A2 (en) Interferon beta antibodies and uses thereof
BR112019008345A2 (en) monoclonal antibodies linked to cd160 transmembrane isoform
MX2022014653A (en) Coronavirus antigen compositions and their uses.
CO2022014884A2 (en) Immunoconjugates
AR120883A1 (en) ANTI-FGFR2B ANTIBODIES
CO2023015915A2 (en) Anti-ccr8 antibodies
BR112019020412A2 (en) compositions and methods to detect lung cancer
AR120884A1 (en) ANTI-FGFR2B ANTIBODIES
AR120886A1 (en) ANTI-FGFR2B ANTIBODIES
DOP2023000005A (en) ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTISPECIFIC BINDING MOLECULES
PE20200613A1 (en) IMMUNOGENIC COMPOSITIONS
CL2024001066A1 (en) New interleukin-7 immunoconjugates
AR124957A2 (en) MODIFIED HINGE ANTIBODY FRAGMENTS AND METHODS OF PREPARATION THEREOF